Jefferson activated participation in the clinical trial in just 14 days, reflecting the organization's commitment to making innovative therapies available to patients with serious and life-threatening conditions as quickly and safely as possible.
Predicting cardiac events in cancer patients with artificial intelligence; understanding limb apraxia; studying the link between stroke recovery and socioeconomic status.
Exploring fracture risk in prostate cancer patients; a role for social media in medical education; real-world treatment of advanced kidney cancer.
